A study of a new treatment for alpha-1 antitrypsin deficiency
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests an experimental drug for people with a specific type of alpha-1 antitrypsin deficiency (Pi*ZZ). It aims to see if the drug is safe and whether it can help improve lung or liver problems caused by the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic test showing Pi*ZZ alpha-1 antitrypsin deficiency.
- You either have mild to moderate lung disease (with good lung function) or stable mild liver disease, or both.
- You have been a non-smoker for at least 1 year before starting the study.
- You are not currently taking alpha-1 antitrypsin augmentation therapy, and you agree not to start it during the study.
- You have no history of allergic reactions to similar drugs or the components used in this treatment.
- You are willing to avoid alcohol for 48 hours before each dose and have no history of heavy drinking.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
This study tests a one-time gene therapy called BEAM-302 that aims to fix the faulty gene causing alpha-1 antitrypsin deficiency (AATD), a condition that damages the lungs and liver. The goal is to improve AAT levels and slow or stop disease progression.
This trial tests a new gene therapy that may fix the genetic cause of alpha-1 antitrypsin deficiency (AATD). It might help protect your lungs and liver from damage.
This trial tests a gene therapy for people with alpha-1 antitrypsin deficiency who have mild to moderate lung disease. The aim is to see if the treatment can improve lung health and is safe.
This study is looking at people with a specific mild form of alpha-1 antitrypsin deficiency (PiMZ) to understand how their lung disease progresses over time. It involves lung function tests and CT scans, and may help researchers learn more about the condition.
Hear when a new Alpha 1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.